compared with treatment with placebo. 5 These results show that ruxolitinib reduces splenomegaly in patients with thalassemia and suggest that targeting EPO-EPOR-JAK2-STAT5 axis may limit the excessive proliferation of erythroid progenitors in spleen.
No takes yet. Share an insight, caveat, or question.
Kommalapati et al. (2017) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: